Trial Outcomes & Findings for Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics (NCT NCT02230189)

Last Updated: 2022-08-16

Results Overview

For each participant with Allergic Asthma, a baseline airway epithelial brushing was performed, allergen was instilled into one segment of the lung, and diluent (control) was instilled into another segment. Both segments were brushed for epithelial cells 24 hours later. After processing brushes to RNA and generating RNA sequencing data, the RNA transcript read counts for each gene underwent variance stabilized log normalization. Then we built a regression model which estimated the difference in miRNA read count in the allergen challenged as compared to the baseline sample and the difference in miRNA read count in the diluent challenged segment as compared to baseline for each participant. The change from baseline read count for each miRNA in the allergen samples was compared to the change in the diluent samples and statistical significance was assessed using the unadjusted p-value(\<0.05). The direction of change does not have clinical significance; this was a mechanistic study.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

28 participants

Primary outcome timeframe

24 hours

Results posted on

2022-08-16

Participant Flow

Participant milestones

Participant milestones
Measure	Allergic Asthmatics(AA) Volunteers with both asthma and allergy (as established by skin prick testing)	Allergic Non-Asthmatics(ANA) Volunteers with allergy (as established by skin prick testing) but without asthma;	Non-Allergic Non-Asthmatics(NANA) Volunteers with neither asthma nor allergy (as established by skin prick testing)
Overall Study STARTED	22	2	4
Overall Study COMPLETED	17	2	3
Overall Study NOT COMPLETED	5	0	1

Reasons for withdrawal

Reasons for withdrawal
Measure	Allergic Asthmatics(AA) Volunteers with both asthma and allergy (as established by skin prick testing)	Non-Allergic Non-Asthmatics(NANA) Volunteers with neither asthma nor allergy (as established by skin prick testing)
Overall Study Physician Decision	1	0
Overall Study Withdrawal by Subject	3	1
Overall Study Lost to Follow-up	1	0

Baseline Characteristics

Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Allergic Non-asthmatics(ANA) n=2 Participants ) Volunteers with allergy (as established by skin prick testing) but without asthma	Non-allergic Non-asthmatics(NANA) n=3 Participants Volunteers with neither asthma nor allergy (as established by skin prick testing)	Allergic Asthmatics(AA) n=17 Participants Volunteers with both asthma and allergy (as established by skin prick testing)	Total n=22 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants
Age, Categorical Between 18 and 65 years	2 Participants n=5 Participants	3 Participants n=7 Participants	16 Participants n=5 Participants	21 Participants n=4 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Age, Continuous	29.5 years STANDARD_DEVIATION 2.12 • n=5 Participants	29 years STANDARD_DEVIATION 5 • n=7 Participants	29.7 years STANDARD_DEVIATION 7.15 • n=5 Participants	29.5 years STANDARD_DEVIATION 9.268 • n=4 Participants
Sex: Female, Male Female	1 Participants n=5 Participants	1 Participants n=7 Participants	11 Participants n=5 Participants	13 Participants n=4 Participants
Sex: Female, Male Male	1 Participants n=5 Participants	2 Participants n=7 Participants	6 Participants n=5 Participants	9 Participants n=4 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=5 Participants	0 Participants n=7 Participants	4 Participants n=5 Participants	5 Participants n=4 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	1 Participants n=5 Participants	3 Participants n=7 Participants	13 Participants n=5 Participants	17 Participants n=4 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	4 Participants n=4 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	3 Participants n=4 Participants
Race (NIH/OMB) White	2 Participants n=5 Participants	1 Participants n=7 Participants	8 Participants n=5 Participants	11 Participants n=4 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	3 Participants n=5 Participants	3 Participants n=4 Participants
Region of Enrollment United States	2 participants n=5 Participants	3 participants n=7 Participants	17 participants n=5 Participants	22 participants n=4 Participants
FEV1	4.52 liters STANDARD_DEVIATION 1.71 • n=5 Participants	4.22 liters STANDARD_DEVIATION 0.397 • n=7 Participants	3.38 liters STANDARD_DEVIATION 0.789 • n=5 Participants	3.6 liters STANDARD_DEVIATION 0.864 • n=4 Participants

PRIMARY outcome

Timeframe: 24 hours

Population: Our pre-specified primary outcome was limited to Allergic Asthmatics only. The rationale for this is that participants without allergy or asthma do not respond to Allergen Challenge and therefore the changes in miRNA are uninformative.

Outcome measures

PRIMARY outcome

Timeframe: 7 days

For each participant with Allergic Asthma, a baseline airway epithelial brushing was performed, allergen was instilled into one segment of the lung, and diluent (control) was instilled into another segment. Both segments were brushed for epithelial cells 7 days later. After processing the brushes to RNA and generating RNA sequencing data, the RNA transcript read counts for each gene underwent variance stabilized log normalization. Then we built a regression model which estimated the difference in miRNA read count in the allergen challenged as compared to the baseline sample and the difference in miRNA read count in the diluent challenged segment as compared to baseline for each participant. The change from baseline read count for each miRNA in the allergen samples was compared to the change in the diluent samples and statistical significance was assessed using the unadjusted p-value(\<0.05). The direction of change does not have clinical significance; this was a mechanistic study.

Outcome measures

Adverse Events

Allergic Asthmatics(AA)

Serious events: 1 serious events

Other events: 2 other events

Deaths: 0 deaths

Allergic Non-Asthmatics(ANA)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Non-Allergic Non-Asthmatics(NANA)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Allergic Asthmatics(AA) n=22 participants at risk Volunteers with both asthma and allergy (as established by skin prick testing)	Allergic Non-Asthmatics(ANA) n=2 participants at risk Volunteers with allergy (as established by skin prick testing) but without asthma;	Non-Allergic Non-Asthmatics(NANA) n=4 participants at risk Volunteers with neither asthma nor allergy (as established by skin prick testing)
Pregnancy, puerperium and perinatal conditions Pregnancy identified during study enrollment	4.5% 1/22 • Number of events 1 • Adverse event data were prospectively collected from the first visit until 48 hours after the last study visit in all participants and until the resolution of any potential adverse event reported by a subject after a study procedure, up to 6 months.	0.00% 0/2 • Adverse event data were prospectively collected from the first visit until 48 hours after the last study visit in all participants and until the resolution of any potential adverse event reported by a subject after a study procedure, up to 6 months.	0.00% 0/4 • Adverse event data were prospectively collected from the first visit until 48 hours after the last study visit in all participants and until the resolution of any potential adverse event reported by a subject after a study procedure, up to 6 months.

Other adverse events

Other adverse events
Measure	Allergic Asthmatics(AA) n=22 participants at risk Volunteers with both asthma and allergy (as established by skin prick testing)	Allergic Non-Asthmatics(ANA) n=2 participants at risk Volunteers with allergy (as established by skin prick testing) but without asthma;	Non-Allergic Non-Asthmatics(NANA) n=4 participants at risk Volunteers with neither asthma nor allergy (as established by skin prick testing)
Respiratory, thoracic and mediastinal disorders Increased systolic blood pressure post-bronchoscopy	4.5% 1/22 • Number of events 1 • Adverse event data were prospectively collected from the first visit until 48 hours after the last study visit in all participants and until the resolution of any potential adverse event reported by a subject after a study procedure, up to 6 months.	0.00% 0/2 • Adverse event data were prospectively collected from the first visit until 48 hours after the last study visit in all participants and until the resolution of any potential adverse event reported by a subject after a study procedure, up to 6 months.	0.00% 0/4 • Adverse event data were prospectively collected from the first visit until 48 hours after the last study visit in all participants and until the resolution of any potential adverse event reported by a subject after a study procedure, up to 6 months.
Respiratory, thoracic and mediastinal disorders Respiratory infection post-bronchoscopy	4.5% 1/22 • Number of events 1 • Adverse event data were prospectively collected from the first visit until 48 hours after the last study visit in all participants and until the resolution of any potential adverse event reported by a subject after a study procedure, up to 6 months.	0.00% 0/2 • Adverse event data were prospectively collected from the first visit until 48 hours after the last study visit in all participants and until the resolution of any potential adverse event reported by a subject after a study procedure, up to 6 months.	0.00% 0/4 • Adverse event data were prospectively collected from the first visit until 48 hours after the last study visit in all participants and until the resolution of any potential adverse event reported by a subject after a study procedure, up to 6 months.

Additional Information

PI: Prescott G. Woodruff, MD, MPH

University of California, San Francisco

Phone: 415-514-2061

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Measure	Allergen Challenge Subjects n=12 Participants Intervention: Segmental airway allergen challenge In this arm, we studied volunteers with both asthma and allergy (as established by skin prick testing) Biological/Vaccine: Segmental airway allergen challenge Procedure/Surgery: Bronchoscopy Diagnostic Test: Methacholine challenge test Diagnostic Test: Spirometry Diagnostic Test: Allergen skin prick test	Diluent Challenge Subjects n=12 Participants Intervention: Segmental airway diluent challenge In this arm, we studied volunteers with both asthma and allergy (as established by skin prick testing).
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR1248	7.02 Normalized log2 copy number Standard Deviation 0.31	7.21 Normalized log2 copy number Standard Deviation 0.48
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR944	7.12 Normalized log2 copy number Standard Deviation 0.19	7.27 Normalized log2 copy number Standard Deviation 0.36
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR6806	6.63 Normalized log2 copy number Standard Deviation 0.22	6.35 Normalized log2 copy number Standard Deviation 0.13
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR103a	12.05 Normalized log2 copy number Standard Deviation 0.38	11.7 Normalized log2 copy number Standard Deviation 0.48
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR454-5p	6.77 Normalized log2 copy number Standard Deviation 0.16	6.57 Normalized log2 copy number Standard Deviation 0.28
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR320e	6.57 Normalized log2 copy number Standard Deviation 0.16	6.69 Normalized log2 copy number Standard Deviation 0.24
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR4521	7.33 Normalized log2 copy number Standard Deviation 0.79	6.74 Normalized log2 copy number Standard Deviation 0.43
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR107	9.63 Normalized log2 copy number Standard Deviation 0.61	9.01 Normalized log2 copy number Standard Deviation 0.98
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR891a	7.02 Normalized log2 copy number Standard Deviation 0.64	6.56 Normalized log2 copy number Standard Deviation 0.46
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR363	9.55 Normalized log2 copy number Standard Deviation 1.16	8.77 Normalized log2 copy number Standard Deviation 1.07
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR181a	8.29 Normalized log2 copy number Standard Deviation 0.33	8.83 Normalized log2 copy number Standard Deviation 0.86
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR130b	6.72 Normalized log2 copy number Standard Deviation 0.17	6.5 Normalized log2 copy number Standard Deviation 0.33
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR365a	6.4 Normalized log2 copy number Standard Deviation 0.14	6.55 Normalized log2 copy number Standard Deviation 0.21
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR135b	6.65 Normalized log2 copy number Standard Deviation 0.22	6.43 Normalized log2 copy number Standard Deviation 0.19
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR1273h	6.53 Normalized log2 copy number Standard Deviation 0.24	6.62 Normalized log2 copy number Standard Deviation 0.33
Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With Allergic Asthma miR3177	6.79 Normalized log2 copy number Standard Deviation 0.26	6.88 Normalized log2 copy number Standard Deviation 0.27

Measure	Allergen Challenge Subjects n=4 Participants Intervention: Segmental airway allergen challenge In this arm, we studied volunteers with both asthma and allergy (as established by skin prick testing) Biological/Vaccine: Segmental airway allergen challenge Procedure/Surgery: Bronchoscopy Diagnostic Test: Methacholine challenge test Diagnostic Test: Spirometry Diagnostic Test: Allergen skin prick test	Diluent Challenge Subjects n=4 Participants Intervention: Segmental airway diluent challenge In this arm, we studied volunteers with both asthma and allergy (as established by skin prick testing).
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR877	5.13 Normalized log2 copy number Standard Deviation 0.42	5.66 Normalized log2 copy number Standard Deviation 0.39
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR6510	7.74 Normalized log2 copy number Standard Deviation 0.57	9.2 Normalized log2 copy number Standard Deviation 0.81
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR3605	5.92 Normalized log2 copy number Standard Deviation 0.61	6.9 Normalized log2 copy number Standard Deviation 0.8
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR3912	5.03 Normalized log2 copy number Standard Deviation 0.53	5.83 Normalized log2 copy number Standard Deviation 0.61
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR15b	6.76 Normalized log2 copy number Standard Deviation 0.33	6.09 Normalized log2 copy number Standard Deviation 0.39
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR127	7.06 Normalized log2 copy number Standard Deviation 0.8	8.54 Normalized log2 copy number Standard Deviation 1.73
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR146a	14.14 Normalized log2 copy number Standard Deviation 1.19	12.73 Normalized log2 copy number Standard Deviation 0.8
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR449b	9.99 Normalized log2 copy number Standard Deviation 0.54	8.84 Normalized log2 copy number Standard Deviation 0.88
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR21-5p	18.02 Normalized log2 copy number Standard Deviation 0.33	17 Normalized log2 copy number Standard Deviation 0.82
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR6842	6.83 Normalized log2 copy number Standard Deviation 0.37	7.67 Normalized log2 copy number Standard Deviation 0.44
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR142-5p	7.68 Normalized log2 copy number Standard Deviation 0.38	6.93 Normalized log2 copy number Standard Deviation 0.66
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR21	7.97 Normalized log2 copy number Standard Deviation 0.49	6.83 Normalized log2 copy number Standard Deviation 0.99
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR493	5.03 Normalized log2 copy number Standard Deviation 0.31	5.66 Normalized log2 copy number Standard Deviation 0.67
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR193a	6.66 Normalized log2 copy number Standard Deviation 0.99	7.46 Normalized log2 copy number Standard Deviation 0.72
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR149	9.98 Normalized log2 copy number Standard Deviation 0.42	10.95 Normalized log2 copy number Standard Deviation 0.4
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR449a	12.46 Normalized log2 copy number Standard Deviation 0.56	11.36 Normalized log2 copy number Standard Deviation 0.95
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR6511a	5.58 Normalized log2 copy number Standard Deviation 0.66	6.46 Normalized log2 copy number Standard Deviation 0.56
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR6843	5.99 Normalized log2 copy number Standard Deviation 0.11	6.8 Normalized log2 copy number Standard Deviation 0.67
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR671	8.53 Normalized log2 copy number Standard Deviation 0.87	9.3 Normalized log2 copy number Standard Deviation 0.73
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR6503	4.93 Normalized log2 copy number Standard Deviation 0.19	5.56 Normalized log2 copy number Standard Deviation 0.59
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR450b	6.05 Normalized log2 copy number Standard Deviation 0.4	5.35 Normalized log2 copy number Standard Deviation 0.52
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR485	5.08 Normalized log2 copy number Standard Deviation 0.62	5.68 Normalized log2 copy number Standard Deviation 0.72
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR6806	5.22 Normalized log2 copy number Standard Deviation 0.38	5.85 Normalized log2 copy number Standard Deviation 0.43
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR3182	5.92 Normalized log2 copy number Standard Deviation 0.2	5.68 Normalized log2 copy number Standard Deviation 0.97
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR142-3p	7.58 Normalized log2 copy number Standard Deviation 0.21	6.72 Normalized log2 copy number Standard Deviation 0.91
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR320d	6.48 Normalized log2 copy number Standard Deviation 0.33	7.09 Normalized log2 copy number Standard Deviation 0.72
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR3928	5.95 Normalized log2 copy number Standard Deviation 0.3	5.24 Normalized log2 copy number Standard Deviation 0.49
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR744	5.6 Normalized log2 copy number Standard Deviation 0.58	5.1 Normalized log2 copy number Standard Deviation 0.47
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR206	5.67 Normalized log2 copy number Standard Deviation 1.06	5.18 Normalized log2 copy number Standard Deviation 0.61
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR30e	11.3 Normalized log2 copy number Standard Deviation 0.29	10.36 Normalized log2 copy number Standard Deviation 0.7
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR4500	6.21 Normalized log2 copy number Standard Deviation 0.41	5.61 Normalized log2 copy number Standard Deviation 0.22
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR125a	13.66 Normalized log2 copy number Standard Deviation 1.47	14.55 Normalized log2 copy number Standard Deviation 1.18
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR99b	13.78 Normalized log2 copy number Standard Deviation 0.31	14.33 Normalized log2 copy number Standard Deviation 0.4
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR1	5.86 Normalized log2 copy number Standard Deviation 0.76	5.17 Normalized log2 copy number Standard Deviation 0.49
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR146b	14.13 Normalized log2 copy number Standard Deviation 0.38	14.72 Normalized log2 copy number Standard Deviation 0.76
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR1255a	5.21 Normalized log2 copy number Standard Deviation 0.54	5.79 Normalized log2 copy number Standard Deviation 0.67
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR223	9.9 Normalized log2 copy number Standard Deviation 0.6	8.9 Normalized log2 copy number Standard Deviation 1.08
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR642a	7.8 Normalized log2 copy number Standard Deviation 0.56	8.32 Normalized log2 copy number Standard Deviation 0.22
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR548ae	5.86 Normalized log2 copy number Standard Deviation 0.24	5.23 Normalized log2 copy number Standard Deviation 0.4
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR146b-3p	7.9 Normalized log2 copy number Standard Deviation 0.35	8.58 Normalized log2 copy number Standard Deviation 0.31
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR181a	8.25 Normalized log2 copy number Standard Deviation 0.32	8.74 Normalized log2 copy number Standard Deviation 0.58
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR4467	5.17 Normalized log2 copy number Standard Deviation 0.47	5.56 Normalized log2 copy number Standard Deviation 0.92
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR1249	5.05 Normalized log2 copy number Standard Deviation 0.35	5.62 Normalized log2 copy number Standard Deviation 0.44
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR766	5.59 Normalized log2 copy number Standard Deviation 0.63	4.98 Normalized log2 copy number Standard Deviation 0.3
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR29c	7.93 Normalized log2 copy number Standard Deviation 0.56	7.09 Normalized log2 copy number Standard Deviation 0.78
Difference in Expression of Epithelial miRNAs (in Read Counts) 7 Days After Allergen-challenge as Compared to 7 Days After Diluent Challenge miR370	5.77 Normalized log2 copy number Standard Deviation 0.76	6.51 Normalized log2 copy number Standard Deviation 1